![Andreas Busch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 5 M $ al 30/06/2026
Andreas Eugen Busch is an Independent Outside Director at Astellas Pharma, Inc. since 2025 and an Independent Director at Sun Pharmaceutical Industries Ltd. since 2026.
Former roles include Vice Chairman-Supervisory Board at Centogene NV from 2022 to 2023, Chief Scientific Officer & Executive VP at Shire Plc from 2018 to 2019, Chief Scientific Officer at Cyclerion Therapeutics, Inc. from 2021 to 2022, Chief Innovation Officer at Absci Corp.
from 2022 to 2026, Head-Global Drug Discovery at Bayer Pharma AG from 2016 to 2017, Executive Vice President & Head-Drug Discovery at Bayer Animal Health from 2016 to 2017, Executive VP & Head-Global Drug Discovery at Bayer HealthCare AG from 2006 to 2015, Head-Cardiovascular Research at Aventis Pharma AG in 2005, Head-Cardiovascular Research at Hoechst Marion Roussel, Inc. from 1997 to 1999, and Global Head-Cardiovascular Research at Sanofi-Aventis Groupe SA from 1997 to 2005.
Also served as Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main and Member-Supervisory Board at Max-Delbrück-Centrum für Molekulare Medizin (MDC).
Education includes a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main conferred in 1989.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ABSCI CORPORATION 0,25 % | 31/03/2026 | 421.446 ( 0,25 % ) | 5 M $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Director/Miembro de la Junta | 12/05/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
| ABSCI CORPORATION | Director/Miembro de la Junta | 04/10/2022 |
| CENTOGENE N.V. | Director/Miembro de la Junta | 12/12/2023 |
| CYCLERION THERAPEUTICS, INC. | Director Técnico/Científico/I+D | 30/09/2022 |
| SHIRE | Director Técnico/Científico/I+D | 01/03/2019 |
Bayer Pharma AG
 Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/12/2017 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 14 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Sun Pharmaceutical Industries Ltd.
 Sun Pharmaceutical Industries Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical ingredients | Health Technology |
Bayer HealthCare AG
 Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals, healthcare supplements and crop herbicides | Health Technology |
Astellas Pharma, Inc.
 Astellas Pharma, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceuticals and related medical products | Health Technology |
Johann Wolfgang Goethe-Universität Frankfurt am Main
 Johann Wolfgang Goethe-Universität Frankfurt am Main Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Aventis Pharma AG | |
Hoechst Marion Roussel, Inc.
 Hoechst Marion Roussel, Inc. Pharmaceuticals: GenericHealth Technology Develops, manufactures and sells generic pharmaceutical products | Health Technology |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Operates as a biomedical research institute | Commercial Services |
Bayer Animal Health
 Bayer Animal Health Pharmaceuticals: MajorHealth Technology Provides healthcare and pharmaceutical medicines | Health Technology |
Sanofi-Aventis Groupe SA
 Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Absci Corp.
 Absci Corp. BiotechnologyHealth Technology Engages in development of cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry | Health Technology |
Cyclerion Therapeutics, Inc.
 Cyclerion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products for serious and orphan diseases | Health Technology |
Centogene NV
 Centogene NV Medical SpecialtiesHealth Technology Provides genetic diagnostic analyses of rare inherited diseases | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
